The results suggest that the combined treatment of pyrotinib and chrysin synergistically inhibits HER2-positive breast cancer cell survival and proliferation in vitro and in vivo by augmenting autophagy, which is accomplished through the miR-16-5p/ZBTB16/G6PD axis. The gene discussed is ERBB2; the disease is breast carcinoma.